Standout Papers

Strategies for subtypes—dealing with the diversity of breast cancer:... 2005 2026 2012 2019 2.8k
  1. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 (2011)
    Aron Goldhirsch, W. C. Wood et al. Annals of Oncology
  2. A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer (2005)
    Beat Thürlimann New England Journal of Medicine
  3. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 (2009)
    Aron Goldhirsch, James N. Ingle et al. Annals of Oncology
  4. Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005 (2005)
    Aron Goldhirsch, John H. Glick et al. Annals of Oncology
  5. Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98 (2007)
    Alan S. Coates, Aparna Keshaviah et al. Journal of Clinical Oncology
  6. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 (2007)
    Aron Goldhirsch, W. C. Wood et al. Annals of Oncology
  7. Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study (2000)
    Jacques Bonneterre, Beat Thürlimann et al. Journal of Clinical Oncology
  8. Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer (2003)
    Aron Goldhirsch, William C. Wood et al. Journal of Clinical Oncology
  9. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019 (2019)
    Harold J. Burstein, Giuseppe Curigliano et al. Annals of Oncology
  10. Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V (2016)
    Marco Colleoni, Zhuoxin Sun et al. Journal of Clinical Oncology

Immediate Impact

4 by Nobel laureates 4 from Science/Nature 148 standout
Sub-graph 1 of 14

Citing Papers

Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides
2023 StandoutNature
Breast cancer
2021 Standout
84 intermediate papers

Works of Beat Thürlimann being referenced

Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
2019 Standout
Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial
2015
and 29 more

Author Peers

Author Last Decade Papers Cites
Beat Thürlimann 10662 9893 5388 212 17.5k
John Forbes 8022 6627 5839 201 16.1k
James N. Ingle 13634 9237 7766 360 23.1k
Marco Colleoni 12237 9906 3016 418 18.9k
Victor G. Vogel 7829 5350 6557 167 15.7k
Kathleen I. Pritchard 15195 9674 4861 368 24.8k
Richard L. Theriault 13484 8853 1785 239 19.9k
Henning T. Mouridsen 7858 6558 2495 242 13.8k
Harold J. Burstein 11624 6896 2262 220 18.6k
Carl Blomqvist 7401 3842 3131 330 13.5k
Lois E. Shepherd 9677 4407 2417 200 15.6k

All Works

Loading papers...

Rankless by CCL
2026